Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Ramping up production, very positive sign

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Mar 19, 2024 11:16am

121 Views

Post# 35940609

RE:RE:RE:RE:RE:Ramping up production, very positive sign

The fever conundrum has been known for years. The designers forgot to inform the respective oncologists that fever and chills was an indication that the virus was working. They lost 1/3 of their trial base guaranteeing the trial as a failure. Millions of dollars and years of research down the drain. Alsop, I was told the FDA helped design the trial. Then there was the Dr. Saab fiasco witn pancreatic cancer trial. This management just can't stop itself from screwing up. Hence $1.40 sp, r/s etc.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”